-
Study aim
-
To assess the effect of erythropoietin versus control group on the short-term prognosis in newborns with hypoxic- ischemic- encephalopathy
-
Design
-
This is a randomized clinical trial, phase II, in which 64 eligible patients will be randomly assigned to the intervention and control groups
-
Settings and conduct
-
The eligible newborns with hypoxic- ischemic- encephalopathy referring to the Fatemieh Hospital in Hamadan city during the study period will be enrolled in the trial and will be randomly assigned to the intervention and control groups through the drawing of lots.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria:
Newborn,
Hypoxic- ischemic- encephalopathy
Exclusion criteria:
Congenital anomalies,
Gestational age less than 36 weeks,
Unperforated anus,
Intracranial hemorrhage
-
Intervention groups
-
Intervention group:
Routine treatment plus intravenous injection of erythropoietin 1000 U/kg/day on the first, second and third days and then every other day on the fifth, seventh, and ninth days to a maximum of 6 doses
Control group:
Just routine treatment
-
Main outcome variables
-
Primary outcome:
Seizure attacks, time of onset of consciousness, the occurrence of death, duration of hospitalization, time to start oral nutrition
Secondary outcome:
Drug complications such as induced topical hypothermia, bradycardia, subcutaneous, and thrombocytopenia